Figure 2.

High levels of ZIC2 predict poor prognosis and early progression in NSCLC patients

(A) Representative images of ZIC2 immunostaining of 43 benign lung lesion tissues, 168 LUAD tissues, and 93 LUSC tissues. Scale bars, upper panels, 200 μm; lower panels, 50 μm. (B) The number of lung tissues stratified by the staining index of ZIC2. (C) Staining index of ZIC2 in different histologic types of NSCLC. Error bar represents the 10^th−90^th percentile. (D and E) Kaplan-Meier survival curve of overall survival (OS) and progression-free survival (PFS) of NSCLC patients with low ZIC2 expression versus high ZIC2 expression. (F and G) Kaplan-Meier survival curve of OS and PFS in NSCLC patients with low ZIC2 expression versus high ZIC2 expression from AE-meta. (H and I) Kaplan-Meier Plotter of OS and PFS in NSCLC patients with low ZIC2 expression versus high ZIC2 expression. p value was determined by log-rank test. HR, hazard ratio; 95% CI, 95% confidence interval.